NEW YORK (GenomeWeb News) – Agilent Technologies today announced a collaboration with Gachon University of Medicine and Science in South Korea to use proteomics and glycoproteomics for biomarker discovery.
Under a memorandum of understanding, the laboratory at the university's College of Pharmacy will serve as Agilent's beta test site for complete glycoproteomics and biomarker discovery workflow solutions.
Agilent did not say what disease areas the research will be directed toward but said Gachon's College of Pharmacy is renowned for research into the prevention and treatment of cancer and diabetes.
Financial and other terms of the deal were not disclosed.
"Glycoproteomics is a key focal point in various aspects of life sciences research," Rod Minett, general manager of Agilent's life sciences business in South Korea and the South Asia Pacific region, said in a statement. "Through this collaboration, we hope to help scientists and researchers advance their research, unlock the genetic causes of disease and accelerate the discovery and development of new drugs."